MCID: RNL014
MIFTS: 81

Renal Cell Carcinoma malady

Categories: Genetic diseases, Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Cell Carcinoma

About this section

Aliases & Descriptions for Renal Cell Carcinoma:

Name: Renal Cell Carcinoma 49 32 10 12 67 65
Renal Carcinoma, Chromophobe, Somatic 49 11
Renal Cell Carcinoma Non-Papillary 67 24
Nonpapillary Renal Cell Carcinoma 10 12
Adenocarcinoma of Kidney 10 67
Carcinoma, Renal Cell 36 24
Hypernephroma 10 67
Rcc 10 67
 
Renal Cell Carcinoma, Clear Cell, Somatic 49
Conventional Renal Cell Carcinoma 65
Conventional Renal Cell Carcinoma 67
Renal Cell Carcinoma, Somatic 49
Common Renal Cell Carcinoma 67
Clear Cell Renal Carcinoma 67
Ccrcc 67
Crcc 67

Characteristics:

HPO:

61
renal cell carcinoma:
Inheritance: sporadic


Classifications:



External Ids:

OMIM49 144700
Disease Ontology10 DOID:0050387, DOID:4450
MeSH36 D002292
NCIt42 C9385
UMLS65 C0007134

Summaries for Renal Cell Carcinoma

About this section
OMIM:49 The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant... (144700) more...

MalaCards based summary: Renal Cell Carcinoma, also known as renal carcinoma, chromophobe, somatic, is related to renal cell carcinoma, papillary and renal clear cell carcinoma, and has symptoms including renal cell carcinoma An important gene associated with Renal Cell Carcinoma is HNF1A (HNF1 Homeobox A), and among its related pathways are Type II diabetes mellitus and Development HGF signaling pathway. The drugs medroxyprogesterone and medroxyprogesterone acetate have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and breast, and related mouse phenotypes are embryo and liver/biliary system.

Disease Ontology:10 A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

UniProtKB/Swiss-Prot:67 Renal cell carcinoma: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.

Novus Biologicals:48 Renal cell carcinoma originates in the proximal renal tube and is the most common form of kidney cancer. Renal cell carcinoma is resistant to radiation therapy and chemotherapy, however some cases respond to immunotherapy. Interleukin-2 has produced remission in some patients, as has functional restoration of the VHL gene.

Wikipedia:68 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Renal Cell Carcinoma

About this section

Diseases in the Renal Cell Carcinoma family:

Hereditary Renal Cell Carcinoma Renal Clear Cell Carcinoma
Familial Renal Cell Carcinoma Renal Cell Carcinoma 4

Diseases related to Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 1666)
idRelated DiseaseScoreTop Affiliating Genes
1renal cell carcinoma, papillary35.4CA9, FLCN, MET, PRCC, TFE3
2renal clear cell carcinoma34.5FLCN, OGG1, PBRM1, RNF139
3mucinous tubular and spindle renal cell carcinoma34.0FLCN, HNF1B
4lupus erythematosus31.6AKT1, MET, PTEN
5cowden syndrome 631.5AKT1, PIK3CA, PTEN
6colorectal cancer30.7AKT1, BHD, CA9, FLCN, IL2, MET
7clear cell adenocarcinoma30.1CA9, HNF1A, VHL
8clear cell renal cell carcinoma12.7
9chromophobe renal cell carcinoma12.6
10multilocular cystic renal cell carcinoma12.5
11clear cell papillary renal cell carcinoma12.5
12sarcomatoid renal cell carcinoma12.4
13hereditary renal cell carcinoma12.4
14multilocular clear cell renal cell carcinoma12.4
15eosinophilic variant of chromophobe renal cell carcinoma12.4
16hereditary conventional renal cell carcinoma12.4
17chromophil renal cell carcinoma12.4
18familial renal cell carcinoma12.4
19renal cell carcinoma associated with neuroblastoma12.4
20hereditary clear cell renal cell carcinoma12.4
21classic variant of chromophobe renal cell carcinoma12.3
22renal cell carcinoma 412.3
23translocation renal cell carcinoma12.3
24mitf-related melanoma and renal cell carcinoma predisposition syndrome12.3
25acquired kidney disease-associated renal cell carcinoma12.3
26hereditary papillary renal cell carcinoma12.3
27kidney cancer11.9
28leiomyomatosis and renal cell cancer11.9
29chromophobe adenocarcinoma11.9
30childhood kidney cell carcinoma11.5
31melanoma, cutaneous malignant 811.3
32papillary serous adenocarcinoma10.8CA9, FLCN, IL2, MET, PRCC, TFE3
33cleft lip and palate malrotation cardiopathy10.8CA9, FLCN, OGG1, PBRM1, RNF139, VHL
34chronic angina10.8FLCN, OGG1, PBRM1, RNF139, VHL
35autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to kiaa0226 deficiency10.8PBRM1, TFE3, VHL
36autosomal recessive myogenic arthrogryposis multiplex congenita10.8PTEN, TFE3, VHL
37hyperaldosteronism10.8FLCN, MET, RNF139
38carney complex-trismus-pseudocamptodactyly syndrome10.8NONO, PRCC, TFE3
39hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome10.8MET, PRCC
40tenosynovitis of foot and ankle10.8AKT1, MET, PIK3CA, PTEN
41cell type cancer10.7AKT1, IL2, PIK3CA, PTEN
42prostatic urethra urothelial carcinoma10.7FLCN, MET, PIK3CA
43von hippel-lindau syndrome10.7
44tracheal lymphoma10.7AKT1, PIK3CA, PTEN
45mediastinum seminoma10.7FLCN, MET
46endotheliitis10.7
47scrotal carcinoma10.7PIK3CA, PTEN
48leukemia10.7
49breast cancer10.6
50collecting duct carcinoma10.6

Graphical network of the top 20 diseases related to Renal Cell Carcinoma:



Diseases related to renal cell carcinoma

Symptoms for Renal Cell Carcinoma

About this section


Clinical features from OMIM:

144700

HPO human phenotypes related to Renal Cell Carcinoma:

id Description Frequency HPO Source Accession
1 renal cell carcinoma HP:0005584

Drugs & Therapeutics for Renal Cell Carcinoma

About this section

FDA approved drugs:

(show all 8)
id Drug Name Active Ingredient(s)15 Company Approval Date
1
Afinitor 15 41 EVEROLIMUS Novartis March 2009
FDA Label: Afinitor
Disease/s that Drug Treats:renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumors/ hormone receptor-positive, HER2-negative breast cancer
Indications and Usage:15 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:13 Serine/threonine-protein kinase mTOR
Mechanism of Action:15 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of thePI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellularprotein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition ofmTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiationfactor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate ofmTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independentactivation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) andreduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shownto reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitrostudies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activityof everolimus in a synergistic manner.Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.
2
Avastin15 41 BEVACIZUMAB Genentech July 2009
FDA Label: Avastin
Disease/s that Drug Treats:renal cell carcinoma & Colorectal Cancer
Indications and Usage:15 Avastin is a vascular endothelial growth factor-specific angiogenesisinhibitor indicated for the treatment of: Metastatic colorectal cancer, with intravenous 5-fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- orfluoropyrimidine-oxaliplatin-based chemotherapy for second-linetreatment in patients who have progressed on a first-line Avastincontainingregimen. (1.1) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxelfor first line treatment of unresectable, locally advanced, recurrent ormetastatic disease. (1.2) Glioblastoma, as a single agent for adult patients with progressive diseasefollowing prior therapy. (1.3)-Effectiveness based on improvement in objective response rate. No dataavailable demonstrating improvement in disease-related symptoms orsurvival with Avastin. Metastatic renal cell carcinoma with interferon alfa (1.4) Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxeland topotecan in persistent, recurrent, or metastatic disease. (1.5) Platinum-resistant recurrent epithelial ovarian, fallopian tube or primaryperitoneal cancer, in combination with paclitaxel, pegylated liposomaldoxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of coloncancer. (1.1)
DrugBank Targets:13 1. Vascular endothelial growth factor A;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:15 
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR)697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction700 of microvascular growth and inhibition of metastatic disease progression
3
Inlyta15 41 AXITINIB Pfizer January 2012
FDA Label: Inlyta
Disease/s that Drug Treats:advanced renal cell carcinoma
Indications and Usage:15 INLYTA is a kinase inhibitor indicated for the treatment of advancedrenal cell carcinoma after failure of one prior systemic therapy. (1)
DrugBank Targets:13 1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3
Mechanism of Action:15 
Target: receptor tyrosine kinases
Action: inhibitor
FDA: Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growthfactor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. Thesereceptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGFmediatedendothelial cell proliferation and survival were inhibited by axitinib in vitro and in mousemodels. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograftmouse models.
4
Nexavar15 41 SORAFENIB TOSYLATE Bayer/Onyx December 2005
FDA Label: Nexavar
Disease/s that Drug Treats:Renal Cell Carcinoma
Indications and Usage:15 NEXAVAR is a kinase inhibitor indicated for the treatment of Unresecta ble hepatocellular carcinoma (1.1) adjust thyroid repla cement therapy in patients with thyroid ca ncer. (5.12) Advanced renal cell carcinoma (1.2) Locally recurrent or meta static, progressive, differentiated thyroid carcinoma refractory to ra dioactive iodine treatment (1.3)
DrugBank Targets:13 1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Vascular endothelial growth factor receptor 3;4. Vascular endothelial growth factor receptor 2;5. Receptor-type tyrosine-protein kinase FLT3;6. Platelet-derived growth factor receptor beta;7. Mast/stem cell growth factor receptor Kit;8. Fibroblast growth factor receptor 1;9. Proto-oncogene tyrosine-protein kinase receptor Ret;10. Vascular endothelial growth factor receptor 1
Mechanism of Action:15 
Target: c-CRAF, BRAF and mutant BRAF, KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß
Action: inhibitor
FDA: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro.Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surfacekinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of thesekinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumorgrowth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumorangiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosiswer e obser ved in models of HCC, RCC, and DTC.
5
Proleukin15 41 ALDESLEUKIN Chiron January 1998
FDA Label: Proleukin
Disease/s that Drug Treats:Metastatic melanoma
Indications and Usage:15 Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cellcarcinoma (metastatic RCC).Proleukin is indicated for the treatment of adults with metastatic melanoma.Careful patient selection is mandatory prior to the administration of Proleukin. See“CONTRAINDICATIONS”, “WARNINGS” and “PRECAUTIONS” sections regarding patientscreening, including recommended cardiac and pulmonary function tests and laboratorytests.Evaluation of clinical studies to date reveals that patients with more favorable ECOGperformance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with ahigher response rate and lower toxicity (See “CLINICAL PHARMACOLOGY” section,“CLINICAL STUDIES” section and “ADVERSE REACTIONS” section). Therefore, selectionof patients for treatment should include assessment of performance status.Experience in patients with ECOG PS >1 is extremely limited.
DrugBank Targets:13 1. Interleukin-2 receptor subunit beta;2. Interleukin-2 receptor subunit alpha;3. Cytokine receptor common subunit gamma
Mechanism of Action:15 
Target: human cells
Action: enhancer of immune response and strnaght ( lymphocytemitogenesis, growth of human interleukin-2 dependent cell lines, lymphocyte cytotoxicity, induction of killer cell activity and interferon-gamma production)
FDA: Proleukin® (aldesleukin) has been shown to possess the biological activities of human nativeinterleukin-2.1,2 In vitro studies performed on human cell lines demonstrate theimmunoregulatory properties of Proleukin, including: a) enhancement of lymphocytemitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines;b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated(LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.The in vivo administration of Proleukin in animals and humans produces multipleimmunological effects in a dose dependent manner. These effects include activation ofcellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and theproduction of cytokines including tumor necrosis factor, IL-1 and gamma interferon. 3 In vivoexperiments in murine tumor models have shown inhibition of tumor growth.4 The exactmechanism by which Proleukin mediates its antitumor activity in animals and humans isunknown.
6
Sutent15 41 SUNITINIB MALATE Pfizer May 2011/ January 2006
FDA Label: Sutent
Disease/s that Drug Treats:pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:15 SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on orintolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors(pNET) in patients with unresectable locally advanced or metastaticdisease. (1.3)
DrugBank Targets:13 1. Platelet-derived growth factor receptor beta;2. Vascular endothelial growth factor receptor 1;3. Mast/stem cell growth factor receptor Kit;4. Vascular endothelial growth factor receptor 2;5. Vascular endothelial growth factor receptor 3;6. Receptor-type tyrosine-protein kinase FLT3;7. Macrophage colony-stimulating factor 1 receptor;8. Platelet-derived growth factor receptor alpha
Mechanism of Action:15 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which areimplicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib wasevaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitorof platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical andcellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primarymetabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR, VEGFR2, KIT) in tumor xenograftsexpressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/orinhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibitgrowth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibitPDGFR- and VEGFR2-dependent tumor angiogenesis in vivo.
7
Torisel15 41 TEMSIROLIMUS Wyeth May 2007
FDA Label: Torisel
Disease/s that Drug Treats:renal cell carcinoma
Indications and Usage:15 TORISEL® is a kinase inhibitor indicated for the treatment of advanced renalcell carcinoma. (1)
DrugBank Targets:13 1. Serine/threonine-protein kinase mTOR
Mechanism of Action:15 
Target: mTOR
Action: inhibitor
FDA: Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds toan intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTORthat controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treatedtumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomalprotein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. Inin vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTORand resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and thevascular endothelial growth factor.
8
Votrient15 41 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009
FDA Label: Votrient
Disease/s that Drug Treats:soft tissue sarcoma/ renal cell carcinoma
Indications and Usage:15 VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: advanced renal cell carcinoma. (1) advanced soft tissue sarcoma who have received prior chemotherapy. (1)Limitation of Use: The efficacy of VOTRIENT for the treatment of patientswith adipocytic soft tissue sarcoma or gastrointestinal stromal tu mors has notbeen demonstrated.
DrugBank Targets:13 1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3;4. Platelet-derived growth factor receptor alpha;5. Platelet-derived growth factor receptor beta;6. Mast/stem cell growth factor receptor Kit;7. Fibroblast growth factor receptor 3;8. Tyrosine-protein kinase ITK/TSK;9. Fibroblast growth factor 1;10. SH2B adapter protein 3
Mechanism of Action:15 
Target: vascular epidermal growth factor receptor (VEGFR) tyrosine kinase
Action: inhibitor
FDA: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factorreceptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-αand -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), andtransmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibitedligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo,pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis ina mouse model, and the growth of some human tumor xenografts in mice.

Drugs for Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 534)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sunitinibapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 2486341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
2
Axitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1100319460-85-06450551
Synonyms:
319460-85-0
790713-39-2
AC-1539
AC1O51X3
AG 013736
AG-013736
AG-013736, Axitinib
AG-13736
AG013736
Axitinib
C503983
CID6450551
 
EC-000.2322
I14-1971
INLYTA
Inlyta
MolPort-006-392-413
N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
S1005_Selleck
SID103905539
ST51054130
UNII-C9LVQ0YUXG
ZINC03816287
axitinib
3
NivolumabapprovedPhase 4, Phase 3, Phase 2, Phase 1198946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
4
Tacrolimusapproved, investigationalPhase 4, Phase 3, Phase 21023104987-11-3445643, 439492, 445647
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
8-DEETHYL-8-[but-3-enyl]-ascomycin
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
FR900506
 
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
Hecoria
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus Hydrate
Tacrolimus anhydrous
Tacrolimus hydrate
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
5
DexmedetomidineapprovedPhase 4470113775-47-668602, 5311068, 56032
Synonyms:
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-trimethylbenzyl)imidazole
(+)-medetomidine
(S)-medetomidine
113775-47-6
4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
DEXMEDETOMIDINE
Dexdor (T)
 
Dexmedetomidin
Dexmedetomidina
Dexmedetomidine
Dexmedetomidine (USAN/INN)
Dexmedetomidine Hydrochloride
Dexmedetomidinum
Dexmédétomidine
MPV 1440
MPV-1440
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
NCGC00025347-01
PRECEDEX
Precedex
Precedex (TN)
Tocris-2023
ZINC04632106
6
NicotineapprovedPhase 497354-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(+-)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(+-)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(R,S)-nicotine
(RS)-nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(±)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
American Fare Nicotine Transdermal System
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Careone Nicotine Transdermal System Step 1
Careone Nicotine Transdermal System Step 2
Careone Nicotine Transdermal System Step 3
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Equaline Nicotine Transdermal System STEP 1
Exchange Select Nicotine Transdermal System STEP 3
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
Habitrol Patch Nicotine Transdermal System, Step 1
Habitrol Patch Nicotine Transdermal System, Step 2
Habitrol Patch Nicotine Transdermal System, Step 3
Healthmart Nicotine Transdermal System STEP 1
Healthmart Nicotine Transdermal System STEP 2
Healthmart Nicotine Transdermal System STEP 3
Kroger Nicotine Transdermal System STEP 1
Kroger Nicotine Transdermal System STEP 2
Kroger Nicotine Transdermal System STEP 3
L(-)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
LS-202
Leader Nicotine
Leader Nicotine Transdermal System STEP 1
Leader Nicotine Transdermal System STEP 2
Leader Nicotine Transdermal System STEP 3
MLS001055457
 
MLS001335905
Mach-Nic
Meijer Nicotine Transdermal System STEP 2
Meijer Nicotine Transdermal System Step 1
Meijer Nicotine Transdermal System Step 3
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm CQ
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine TRANSDERMAL SYSTEM
Nicotine Transdermal System PATCH KIT
Nicotine Transdermal System STEP 1
Nicotine Transdermal System STEP 2
Nicotine Transdermal System STEP 3
Nicotine Transdermal System Step 1
Nicotine Transdermal System Step 2
Nicotine Transdermal System Step 3
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotine transdermal system
Nicotrol
Nicotrol (professional Sample)
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
Rite Aid Nicotine Transdermal System Step 1
Rite Aid Nicotine Transdermal System Step 2
Rite Aid Nicotine Transdermal System Step 3
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Safeway Nicotine Transdermal System STEP 1
Safeway Nicotine Transdermal System STEP 2
Safeway Nicotine Transdermal System STEP 3
Smart Sense Nicotine
Sunmark Nicotine
Sunmark Nicotine Transdermal System STEP 1
Sunmark Nicotine Transdermal System STEP 2
Sunmark Nicotine Transdermal System STEP 3
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
7
Mycophenolate mofetilapproved, investigationalPhase 4, Phase 2, Phase 1898128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate Mofetil
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
8
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
9
Peginterferon alfa-2aapproved, investigationalPhase 4, Phase 1, Phase 2537198153-51-45360545
Synonyms:
198153-51-4
D02747
Pegasys
 
Pegasys (TN)
Peginterferon alfa-2a
Peginterferon alfa-2a (USAN/INN)
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
10
RibavirinapprovedPhase 4, Phase 394836791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
Ibavyr
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
Moderiba
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
 
NSC 163039
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribasphere Ribapak
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
11
Sorafenibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1671284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib Tosylate
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
12
GemcitabineapprovedPhase 4, Phase 2, Phase 3, Phase 1188195058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine Hydrochloride
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
13
EtoposideapprovedPhase 4, Phase 3, Phase 2, Phase 1116933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
 
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide Phosphate
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
14
Irinotecanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1104497682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
15
Midazolamapproved, illicitPhase 4, Phase 163559467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
Dormicum
 
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam Hydrochloride
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
16
Mycophenolic acidapprovedPhase 4, Phase 2, Phase 189824280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Melbex
 
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolic Acid
Mycophenolsaeure
Myfortic
17
AldesleukinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 038785898-30-2
Synonyms:
IL-2
Interleukin-2 precursor
 
Proleukin
T-cell growth factor
TCGF
18
Bevacizumabapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 11875216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
19
Miconazoleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
20
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 11797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
21
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
22
AzathioprineapprovedPhase 4153446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
 
HMS1920E17
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
23
Caffeineapproved, NutraceuticalPhase 433958-08-22519
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-Trimethylxanthine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
1-Methyl-Theobromine
1-methyltheobromine
137X
1gfz
1l5q
1l7x
27602_FLUKA
2a3b
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
3,7-dihydro-1,3,7-trimethyl-1H-purine
5-26-13-00558 (Beilstein)
58-08-2
7-Methyl Theophylline
7-Methyltheophylline
7-methyltheophylline
71701-02-5
75035_FLUKA
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert
Alert-Pep
Alert-pep
Allertness Aid
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
Awake
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
BRN 0017705
BSPBio_001921
Berlin-Chemie Brand of Caffeine
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
Bristol-Myers Squibb Brand of Caffeine
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
CU-01000012617-3
Cafamil
Cafcit
Cafecon
Cafeina
Cafergot
Cafeína
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
Caffeine
Caffeine (USP)
Caffeine (natural)
Caffeine Citrate
Caffeine Pure
Caffeine [BAN:JAN]
Caffeine citrate
Caffeine solution
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeine, anhydrous
Caffeine, synthetic
Caffine
Cafipel
Caféine
Circle K Nosnooze
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum Purrum
Compound 65
Conrx Alert
D002110
D00528
DB00201
DHC Plus
DHCplus
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
Diurex Ultra
Diurex WaterCaps
DivK1c_000730
Drowz Away Maximum strength
Durvitan
EINECS 200-362-1
EU-0100228
Eldiatric C
Enerjets
Equaline Stay Awake
Ercatab
Esgic
Esgic-Plus
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline Brand of Caffeine
Good Neighbor Pharmacy Stay Awake
Good Sense Stay Awake
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Health Mart Stay Awake
Healthy Accents Stay Awake
Hycomine
Hycomine Compound
I14-4386
IDI1_000730
 
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
LS-237
Lanorinal
Leader Alertness Aid
Lil Drug Store Nosnooze
Lopac-C-0750
Lopac0_000228
MEGxp0_001350
MLS001055341
MLS001056714
MLS001066409
Mateina
Mateína
Maximum Strength Caffeine
Maximum Strength Snapback Stimulant Powders
Maximum Strength Stay Awake
Medigesic Plus
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MolMap_000054
MolPort-000-730-850
Monohydrate Caffeine
Monomethyl Derivative of Theophylline
Monomethyl derivative of Theophylline
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
NCI-C02733
NCIOpen2_008255
NINDS_000730
NSC 5036
NSC5036
Nano Ppc
Natural Caffeinum
Nix Nap
No Doz
No-Doz
Nodaca
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Passauer Brand of Caffeine
Pep-Back
Pep-back Peak Performance
Pep-back Ultra
Percoffedrinol N
Percutafeine
Phensal
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-Pep
Refresh'n
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
SPECTRUM1500155
STK177283
Seid Brand of Caffeine
Smart Sense Stay Awake
Sohmed Alertness Aid
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Spectrum_001301
Stay Alert Aid
Stay Awake
Stay Awake Maximum Strength
Stay Awake Maximum strength
Stim
Sunmark Stay Awake
Synalgos-Dc
TNP00310
Teina
Thein
Theine
Theobromine ME
Theobromine Me
Theophylline ME
Theophylline Me
Theophylline, 7-methyl
Thompson Brand 1 of Caffeine
Thompson Brand 2 of Caffeine
Tirend
Topcare Stay Awake maximum strength
Tri-Aqua
Triad
UNII-3G6A5W338E
Ultra Pep-Back
Vivarin
W222402_ALDRICH
WLN: T56 BN DN FNVNVJ B1 F1 H1
Wake-Up
Wigraine
Xanthine, 1,3,7-trimethyl
ZINC00001084
bmse000206
cafeine
caffeine
caffenium
component of Cafergot
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
teina
24Etoposide phosphatePhase 4, Phase 3, Phase 2, Phase 11169
25Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 117220
26Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 110422
27CyclosporinsPhase 4, Phase 1, Phase 2873
28Calcineurin InhibitorsPhase 4, Phase 3, Phase 2, Phase 11223
29interferonsPhase 4, Phase 3, Phase 2, Phase 11930
30topoisomerase I inhibitorsPhase 4, Phase 3, Phase 2, Phase 11131
31Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 118483
32Antineoplastic Agents, PhytogenicPhase 4, Phase 3, Phase 2, Phase 1, Phase 04294
33Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 2, Phase 1, Phase 05184
34Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 18496
35HormonesPhase 4, Phase 3, Phase 2, Phase 1, Phase 011748
36Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 19140
37Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 1, Phase 23611
38Angiogenesis InhibitorsPhase 4, Phase 3, Phase 1, Phase 23688
39Imatinib MesylatePhase 4, Phase 2, Phase 1577123596
40Interferon-alphaPhase 4, Phase 3, Phase 2, Phase 11028
41Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 15770
42Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 18071
43Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13015
44Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 15971
45Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 14081
46AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 19454
47Central Nervous System DepressantsPhase 4, Phase 2, Phase 310016
48Anti-Anxiety AgentsPhase 41529
49
Erlotinib HydrochloridePhase 4, Phase 3, Phase 2, Phase 1781183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
50GABA ModulatorsPhase 4657

Interventional clinical trials:

(show top 50)    (show all 1554)
idNameStatusNCT IDPhase
1Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab TreatmentCompletedNCT02056587Phase 4
2SUTENT® In The First Line Treatment Of Renal Cell CarcinomaCompletedNCT00460798Phase 4
3Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell CarcinomaCompletedNCT00706706Phase 4
4Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00006864Phase 4
5Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.CompletedNCT01339962Phase 4
6Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone MetastasisCompletedNCT00172003Phase 4
7Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
8Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingCompletedNCT00365508Phase 4
9Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal TumoursCompletedNCT02016391Phase 4
10Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant RecipientsCompletedNCT00129961Phase 4
11Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic FactorsRecruitingNCT02700568Phase 4
12First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell CarcinomaRecruitingNCT01521715Phase 4
13A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.RecruitingNCT01206764Phase 4
14Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or PazopanibRecruitingNCT01514448Phase 4
15Post Marketing Surveillance for ICE-SENSE™3 a Cryotherapy Treatment of Renal Cell CarcinomaRecruitingNCT02399124Phase 4
16A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell CarcinomaRecruitingNCT02596035Phase 4
17Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF TherapyRecruitingNCT02570789Phase 4
18Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)RecruitingNCT02338570Phase 4
19Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaRecruitingNCT02555748Phase 4
20Study to the Optimal Duration of Therapy With Oral Angiogenesis InhibitorsRecruitingNCT00777504Phase 4
21Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver CancerRecruitingNCT02081755Phase 4
22Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung CancerRecruitingNCT02348450Phase 4
23Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)Active, not recruitingNCT01266837Phase 4
24Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell CarcinomaTerminatedNCT00930345Phase 4
25Phase IV Randomization to On-Going Treatment to Evaluate Sustained SorafenibTerminatedNCT00352859Phase 4
26Cost Effectiveness Of Sunitinib In Central America And CaribbeanTerminatedNCT01033981Phase 4
27Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino PatientsTerminatedNCT01073644Phase 4
28Hydroxyethyl Starch and Renal Function After Laparoscopic NephrectomyTerminatedNCT01486550Phase 4
29Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive ProtocolTerminatedNCT01797315Phase 4
30Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive ProtocolTerminatedNCT00866684Phase 4
31Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral LoadTerminatedNCT00977054Phase 4
32Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney CancerWithdrawnNCT01353794Phase 4
33A Post Marketing Surveillance As Required By Philippine Food And Drug AdministrationWithdrawnNCT01781442Phase 4
34Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-AntibodyCompletedNCT00606632Phase 3
35Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.CompletedNCT00502034Phase 3
36Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell CancerCompletedNCT00387764Phase 3
37Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)CompletedNCT00586105Phase 3
38Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)CompletedNCT00478114Phase 3
39An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell CarcinomaCompletedNCT00492986Phase 3
40Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney CancerCompletedNCT01064310Phase 3
41Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)CompletedNCT00072046Phase 3
42Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell CancerCompletedNCT00073307Phase 3
43Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney CancerCompletedNCT00492258Phase 3
44Study Evaluating Interferon And CCI-779 In Advanced Renal Cell CarcinomaCompletedNCT00065468Phase 3
45Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney CancerCompletedNCT00002737Phase 3
46Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney CancerCompletedNCT00002473Phase 3
47AE-941 in Treating Patients With Metastatic Kidney CancerCompletedNCT00005995Phase 3
48Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney CancerCompletedNCT00003126Phase 3
49Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00018941Phase 3
50Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney CancerCompletedNCT00416429Phase 3

Search NIH Clinical Center for Renal Cell Carcinoma

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: carcinoma, renal cell

Genetic Tests for Renal Cell Carcinoma

About this section

Anatomical Context for Renal Cell Carcinoma

About this section

MalaCards organs/tissues related to Renal Cell Carcinoma:

33
Kidney, Lung, Breast, Endothelial, Bone, Brain, Liver

Animal Models for Renal Cell Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Renal Cell Carcinoma:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538010.8AKT1, FLCN, HNF1B, MET, NONO, PBRM1
2MP:000537010.8AKT1, HNF1A, HNF1B, IL2, MET, OGG1
3MP:000537910.8AKT1, CA9, HNF1A, HNF1B, IL2, MET
4MP:000200610.7AKT1, FLCN, IL2, MET, OGG1, PIK3CA
5MP:000538710.5AKT1, FLCN, HNF1B, IL2, MET, OGG1
6MP:000536910.4AKT1, HNF1A, HNF1B, MET, PIK3CA, PTEN
7MP:001076810.2AKT1, CA9, FLCN, HNF1A, HNF1B, IL2

Publications for Renal Cell Carcinoma

About this section

Articles related to Renal Cell Carcinoma:

(show top 50)    (show all 4678)
idTitleAuthorsYear
1
Pseudomembranous Type of Oral Candidiasis is Associated with Decreased Salivary Flow Rate and Secretory Immunoglobulin A Levels. (25682023)
2015
2
Thermal sensitisation by lonidamine of human melanoma cells grown at low extracellular pH. (24295212)
2013
3
Type 2 diabetes mellitus and invokana: an FDA approved drug. (24160357)
2013
4
Cryptic residual GALT activity is a potential modifier of scholastic outcome in school age children with classic galactosemia. (23319291)
2013
5
Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema. (24379923)
2013
6
Mitochondrial DNA polymorphisms are associated with the longevity in the Guangxi Bama population of China. (22729909)
2012
7
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. (21701070)
2011
8
Polymorphisms of human nonmetastatic clone 23 type 1 gene and neoplastic lesions of uterine cervix. (20601538)
2010
9
Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1. (19144646)
2009
10
Insulin response to oral glucose load is associated with coronary artery disease in subjects with normal glucose tolerance. (18270458)
2008
11
Genetic determination of irritable bowel syndrome. (19034965)
2008
12
The evaluation of markers of prostatic inflammation and function of the prostate gland in patients with chronic prostatitis. (18661262)
2008
13
Expression of histamine H4 receptor in human osteoarthritic synovial tissue. (18345487)
2008
14
Hemarthrosis due to a rare cause of hemorrhagic diathesis: Ehlers-Danlos syndrome. (18432503)
2008
15
SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. (17592081)
2007
16
Unexpected superimposition of nutcracker effect in various conditions: is it an unrecognized confounding factor? Comment on: Henoch-Schonlein purpura presenting duodenal involvement similar to superior mesenteric artery syndrome in a girl. (Eur J Pediatr. 2006 Sep 29; [Epub ahead of print]). (17180389)
2007
17
Effect of HLA-A2 allele disparity on clinical outcome in hematopoietic cell transplantation from unrelated donors. (17445159)
2007
18
Results of double-blind placebo-controlled crossover study of sildenafil citrate (Viagra) in women suffering from obstructed voiding or retention associated with the primary disorder of sphincter relaxation (Fowler's Syndrome). (16884844)
2007
19
Bilateral acute anterior uveitis as a side effect of trimethoprim. (16751748)
2007
20
Expression of lysosome-associated membrane protein 1 (Lamp-1) and galectins in human keratinocytes is regulated by differentiation. (16710742)
2006
21
Study on the correlation between the expressions of nm23H1 mRNA, VEGF-C mRNA and lymphatic metastases, survival rate with gastric cancer]. (16944571)
2006
22
Radiofrequency ablation for cystic adenomyosis: a case report. (16779992)
2006
23
Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. (15195070)
2004
24
An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. (15498586)
2004
25
Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine. (15215330)
2004
26
Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. (14987729)
2004
27
Genetic analysis of benign ovarian tumors. (12712441)
2003
28
The effects of continuous stimulation with different doses of parathyroid hormone 1-34 fragment on human SaoS-2 cells]. (12816700)
2003
29
Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. (11813134)
2002
30
Molecular and cellular characterization of transferrin receptor 2. (12139409)
2002
31
Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. (12210076)
2002
32
PKA modulation of Kv4.2-encoded A-type potassium channels requires formation of a supramolecular complex. (12451113)
2002
33
Aerococcus urinae in urinary tract infections. (10747177)
2000
34
RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. (10698491)
2000
35
Diffuse esophageal leiomyomatosis: another cause of pseudoachalasia. (14601910)
2000
36
The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. (10579999)
1999
37
S-100 and bovine spongiform encephalopathy. (10461739)
1999
38
Strain-specific prion-protein conformation determined by metal ions. (10559865)
1999
39
Production of the islet cell antigen ICA69 (p69) with baculovirus expression system: analysis with a solid-phase time-resolved fluorescence method of sera from patients with IDDM and rheumatoid arthritis. (10433084)
1999
40
Cystic medial degeneration of the aorta is associated with p53 accumulation, Bax upregulation, apoptotic cell death, and cell proliferation. (10455077)
1999
41
Hepatosplenic gammadelta T-cell lymphoma: ultrastructural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte differentiation. (9191001)
1997
42
The effect of eugenol-containing temporary cement on the bond strength of two resin composite core materials to dentin. (9497767)
1997
43
Molecular genetic studies in muscle phosphoglycerate mutase (PGAM-M) deficiency. (7603528)
1995
44
The N-terminal region of the human immunodeficiency virus envelope glycoprotein gp120 contains potential binding sites for CD4. (2339113)
1990
45
Forebrain mechanisms in neurogenic hypertension. (3690390)
1987
46
Treatment of a metabolic disease, scurvy, by administration of the missing enzyme. (3778677)
1986
47
Duodenal diaphragm associated with superior mesenteric artery syndrome. (7457748)
1981
48
Immunofluorescent localization of placental lactogen, chorionic gonadotrophin and its alpha and beta subunits in organ cultures of human placenta. (6160572)
1980
49
Recurrent spontaneous pneumothorax in diffuse scleroderma. Report of a case. (5907810)
1966
50
LUMBAR SYMPATHECTOMY IN ARTERIOSCLEROSIS OBLITERANS. (14179033)
1964

Variations for Renal Cell Carcinoma

About this section

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma:

67
id Symbol AA change Variation ID SNP ID
1FLCNp.Arg239CysVAR_066026rs78683075
2VHLp.Leu163ProVAR_034998rs28940297

Clinvar genetic disease variations for Renal Cell Carcinoma:

5
id Gene Variation Type Significance SNP ID Assembly Location
1HNF1ANM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs)duplicationPathogenicrs587776825GRCh37Chr 12, 121432125: 121432125

Cosmic variations for Renal Cell Carcinoma:

7 (show top 50)    (show all 4095)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM18346VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
2COSM18346VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
3COSM18346VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
4COSM18346VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
5COSM18346VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
6COSM18346VHLkidney,NS,carcinoma,papillary renal cell carcinoma3
7COSM18346VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
8COSM18351VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
9COSM18351VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
10COSM18351VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
11COSM18351VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
12COSM18351VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
13COSM18351VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
14COSM18351VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
15COSM18351VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
16COSM18351VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
17COSM18346VHLkidney,NS,carcinoma,papillary renal cell carcinoma3
18COSM18346VHLkidney,NS,carcinoma,papillary renal cell carcinoma3
19COSM18290VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
20COSM18290VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
21COSM18290VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
22COSM18290VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
23COSM18290VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
24COSM18289VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
25COSM18290VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
26COSM18328VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
27COSM18328VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
28COSM18346VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
29COSM18346VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
30COSM18346VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
31COSM18343VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
32COSM18343VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
33COSM18328VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
34COSM18343VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
35COSM18351VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
36COSM18351VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
37COSM18358VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
38COSM18372VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
39COSM18372VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
40COSM18358VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
41COSM18358VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
42COSM18355VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
43COSM18355VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
44COSM18372VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
45COSM18374VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
46COSM18379VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
47COSM18379VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
48COSM18379VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
49COSM18379VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3
50COSM18379VHLkidney,NS,carcinoma,clear cell renal cell carcinoma3

Expression for genes affiliated with Renal Cell Carcinoma

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Renal Cell Carcinoma patients vs. healthy controls: 32 (show all 278)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1SLC12A1solute carrier family 12 (sodium/potassium/chloride transporter), member 1Kidney-9.350.000
2CALB1calbindin 1, 28kDaKidney-8.950.000
3FXYD4FXYD domain containing ion transport regulator 4Kidney-8.290.000
4CLDN8claudin 8Kidney-8.200.000
5KCNJ1potassium channel, inwardly rectifying subfamily J, member 1Kidney-8.200.000
6NPHS2nephrosis 2, idiopathic, steroid-resistant (podocin)Kidney-8.180.000
7MUC15mucin 15, cell surface associatedKidney-7.960.000
8SCNN1Gsodium channel, non voltage gated 1 gamma subunitKidney-7.910.000
9HPD4-hydroxyphenylpyruvate dioxygenaseKidney-7.780.000
10FABP1fatty acid binding protein 1, liverKidney-7.740.000
11DNASE1deoxyribonuclease IKidney-7.590.000
12SLC7A13solute carrier family 7 (anionic amino acid transporter), member 13Kidney-7.290.000
13ANGPTL4angiopoietin-like 4Kidney+7.250.000
14TNFAIP6tumor necrosis factor, alpha-induced protein 6Kidney+7.160.000
15ATP6V0A4ATPase, H+ transporting, lysosomal V0 subunit a4Kidney-7.130.000
16PCP4Purkinje cell protein 4Kidney-7.130.000
17KNG1kininogen 1Kidney-7.120.000
18TYRP1tyrosinase-related protein 1Kidney-7.100.000
19FGF9fibroblast growth factor 9Kidney-6.990.000
20EGFepidermal growth factorKidney-6.920.000
21RALYLRALY RNA binding protein-likeKidney-6.810.000
22PVALBparvalbuminKidney-6.730.000
23KCNJ10potassium channel, inwardly rectifying subfamily J, member 10Kidney-6.690.000
24TMEM213transmembrane protein 213Kidney-6.640.000
25SLC22A8solute carrier family 22 (organic anion transporter), member 8Kidney-6.580.000
26IRX2iroquois homeobox 2Kidney-6.560.000
27SLC26A7solute carrier family 26 (anion exchanger), member 7Kidney-6.560.000
28SLC4A1solute carrier family 4 (anion exchanger), member 1 (Diego blood group)Kidney-6.530.000
29GPC5glypican 5Kidney-6.530.000
30RHCGRh family, C glycoproteinKidney-6.520.000
31SOSTsclerostinKidney-6.510.000
32SFRP1secreted frizzled-related protein 1Kidney-6.490.000
33HEPACAM2HEPACAM family member 2Kidney-6.450.000
34NELL1neural EGFL like 1Kidney-6.380.000
35SERPINA5serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5Kidney-6.340.000
36RAB25RAB25, member RAS oncogene familyKidney-6.320.000
37TMPRSS2transmembrane protease, serine 2Kidney-6.310.000
38TMEM52Btransmembrane protein 52BKidney-6.280.000
39ERBB4erb-b2 receptor tyrosine kinase 4Kidney-6.260.000
40SOSTDC1sclerostin domain containing 1Kidney-6.250.000
41SH3GL2SH3-domain GRB2-like 2Kidney-6.160.000
42ALDOBaldolase B, fructose-bisphosphateKidney-6.130.003
43APOC1apolipoprotein C-IKidney+6.110.000
44UMODuromodulinKidney-6.070.000
45NPTX2neuronal pentraxin IIKidney+6.050.000
46LOC284578uncharacterized LOC284578Kidney-6.020.000
47ESRRBestrogen-related receptor betaKidney-5.990.000
48SLC13A3solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3Kidney-5.960.001
49TSPAN8tetraspanin 8Kidney-5.960.000
50WNK4WNK lysine deficient protein kinase 4Kidney-5.940.000
51DIO1deiodinase, iodothyronine, type IKidney-5.930.000
52PTHLHparathyroid hormone-like hormoneKidney+5.880.001
53NDUFA4L2NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2Kidney+5.760.000
54ATP6V1G3ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G3Kidney-5.730.000
55NOS1nitric oxide synthase 1 (neuronal)Kidney-5.730.000
56FABP7fatty acid binding protein 7, brainKidney+5.710.042
57SIM2single-minded family bHLH transcription factor 2Kidney-5.660.000
58XPNPEP2X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-boundKidney-5.650.000
59G6PCglucose-6-phosphatase, catalytic subunitKidney-5.640.013
60SCNN1Asodium channel, non voltage gated 1 alpha subunitKidney-5.630.002
61ATP6V1B1ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1Kidney-5.620.000
62HSD11B2hydroxysteroid (11-beta) dehydrogenase 2Kidney-5.600.000
63CCL20chemokine (C-C motif) ligand 20Kidney+5.550.007
64HS6ST2heparan sulfate 6-O-sulfotransferase 2Kidney-5.520.000
65CDCA2cell division cycle associated 2Kidney+5.520.000
66DPEP1dipeptidase 1 (renal)Kidney-5.490.000
67SLC4A9solute carrier family 4, sodium bicarbonate cotransporter, member 9Kidney-5.490.000
68C16orf89chromosome 16 open reading frame 89Kidney-5.480.000
69CTXN3cortexin 3Kidney-5.470.001
70LOC285556uncharacterized LOC285556Kidney-5.470.000
71FAM3Bfamily with sequence similarity 3, member BKidney-5.430.000
72HRGhistidine-rich glycoproteinKidney-5.400.000
73PLGplasminogenKidney-5.400.000
74STC2stanniocalcin 2Kidney+5.390.000
75ENPP6ectonucleotide pyrophosphatase/phosphodiesterase 6Kidney-5.380.000
76MST1Lmacrophage stimulating 1-likeKidney-5.340.000
77PAHphenylalanine hydroxylaseKidney-5.320.003
78MFSD4major facilitator superfamily domain containing 4Kidney-5.310.000
79SCNN1Bsodium channel, non voltage gated 1 beta subunitKidney-5.290.000
80PRDM16PR domain containing 16Kidney-5.290.000
81FAM151Afamily with sequence similarity 151, member AKidney-5.290.004
82MALmal, T-cell differentiation proteinKidney-5.290.001
83CA10carbonic anhydrase XKidney-5.290.000
84GRM1glutamate receptor, metabotropic 1Kidney-5.280.000
85RANBP3LRAN binding protein 3-likeKidney-5.270.000
86CLCNKBchloride channel, voltage-sensitive KbKidney-5.260.000
87NRKNik related kinaseKidney-5.260.000
88VTCN1V-set domain containing T cell activation inhibitor 1Kidney-5.260.000
89ESRP1epithelial splicing regulatory protein 1Kidney-5.250.001
90TOP2Atopoisomerase (DNA) II alphaKidney+5.240.000
91CYP4F2cytochrome P450, family 4, subfamily F, polypeptide 2Kidney-5.210.000
92ZNF44zinc finger protein 44Kidney-5.190.000
93DUSP9dual specificity phosphatase 9Kidney-5.150.000
94AQP2aquaporin 2 (collecting duct)Kidney-5.150.000
95SLC22A7solute carrier family 22 (organic anion transporter), member 7Kidney-5.130.008
96VGLL1vestigial-like family member 1Kidney-5.120.000
97EGLN3egl-9 family hypoxia-inducible factor 3Kidney+5.120.000
98DMRT2doublesex and mab-3 related transcription factor 2Kidney-5.110.000
99TACSTD2tumor-associated calcium signal transducer 2Kidney-5.110.000
100CASRcalcium-sensing receptorKidney-5.110.000
101SLC13A2solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2Kidney-5.110.000
102UPP2uridine phosphorylase 2Kidney-5.100.000
103PLPPR1phospholipid phosphatase related 1Kidney-5.080.000
104CRYAAcrystallin, alpha AKidney-5.080.000
105NKG7natural killer cell granule protein 7Kidney+5.070.000
106C7complement component 7Kidney-5.070.002
107RALGAPA2Ral GTPase activating protein, alpha subunit 2 (catalytic)Kidney-5.050.000
108NNMTnicotinamide N-methyltransferaseKidney+5.050.000
109MYO3Bmyosin IIIBKidney-5.050.001
110CWH43cell wall biogenesis 43 C-terminal homologKidney-5.030.002
111ADH1Balcohol dehydrogenase 1B (class I), beta polypeptideKidney-5.020.001
112TMEM61transmembrane protein 61Kidney-4.990.000
113SLC22A12solute carrier family 22 (organic anion/urate transporter), member 12Kidney-4.970.001
114ELF5E74-like factor 5 (ets domain transcription factor)Kidney-4.960.000
115TOX3TOX high mobility group box family member 3Kidney-4.940.019
116FLJ22763uncharacterized LOC401081Kidney-4.940.006
117FABP6fatty acid binding protein 6, ilealKidney+4.940.005
118TCEAL2transcription elongation factor A (SII)-like 2Kidney-4.920.003
119CA9carbonic anhydrase IXKidney+4.920.000
120LOC149703uncharacterized LOC149703Kidney-4.920.001
121TMEM45Btransmembrane protein 45BKidney-4.920.003
122EHFets homologous factorKidney-4.900.000
123ATP6V1C2ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C2Kidney-4.900.000
124ISG20interferon stimulated exonuclease gene 20kDaKidney+4.890.000
125BMPR1Bbone morphogenetic protein receptor, type IBKidney-4.880.001
126SLC22A6solute carrier family 22 (organic anion transporter), member 6Kidney-4.870.011
127SCN2Asodium channel, voltage gated, type II alpha subunitKidney-4.870.001
128SLC7A8solute carrier family 7 (amino acid transporter light chain, L system), member 8Kidney-4.860.000
129KLRG2killer cell lectin-like receptor subfamily G, member 2Kidney-4.840.000
130GGT6gamma-glutamyltransferase 6Kidney-4.830.000
131ACPPacid phosphatase, prostateKidney-4.830.000
132PROM2prominin 2Kidney-4.770.000
133PLCXD3phosphatidylinositol-specific phospholipase C, X domain containing 3Kidney-4.770.000
134CLDN16claudin 16Kidney-4.770.000
135AFMafaminKidney-4.760.001
136KCNE1potassium channel, voltage gated subfamily E regulatory beta subunit 1Kidney-4.760.000
137CLIC5chloride intracellular channel 5Kidney-4.730.000
138ADGRF1adhesion G protein-coupled receptor F1Kidney-4.720.000
139GATA3GATA binding protein 3Kidney-4.720.002
140ATP6V0D2ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2Kidney-4.710.000
141HK2hexokinase 2Kidney+4.710.000
142TFCP2L1transcription factor CP2-like 1Kidney-4.710.000
143GABRA2gamma-aminobutyric acid (GABA) A receptor, alpha 2Kidney-4.700.000
144CLDN19claudin 19Kidney-4.680.000
145PPP1R1Aprotein phosphatase 1, regulatory (inhibitor) subunit 1AKidney-4.670.021
146KISS1RKISS1 receptorKidney+4.670.001
147ADH1Calcohol dehydrogenase 1C (class I), gamma polypeptideKidney-4.650.000
148TFAP2Btranscription factor AP-2 beta (activating enhancer binding protein 2 beta)Kidney-4.630.000
149PTGER1prostaglandin E receptor 1 (subtype EP1), 42kDaKidney-4.620.000
150STAP1signal transducing adaptor family member 1Kidney-4.610.000
151ARL11ADP-ribosylation factor-like 11Kidney+4.600.000
152LINC00982long intergenic non-protein coding RNA 982Kidney-4.600.000
153CHL1cell adhesion molecule L1-likeKidney-4.600.001
154FOXI1forkhead box I1Kidney-4.590.000
155C5orf46chromosome 5 open reading frame 46Kidney+4.590.016
156ANKRD2ankyrin repeat domain 2 (stretch responsive muscle)Kidney-4.580.001
157ALBalbuminKidney-4.570.000
158L1CAML1 cell adhesion moleculeKidney-4.570.004
159PDGFRAplatelet-derived growth factor receptor, alpha polypeptideKidney-4.560.009
160FGF1fibroblast growth factor 1 (acidic)Kidney-4.560.000
161C3complement component 3Kidney+4.550.000
162TMEM207transmembrane protein 207Kidney-4.550.000
163CTHRC1collagen triple helix repeat containing 1Kidney+4.540.000
164KLHL14kelch-like family member 14Kidney-4.530.001
165ANGPTL1angiopoietin-like 1Kidney-4.530.002
166SLC12A3solute carrier family 12 (sodium/chloride transporter), member 3Kidney-4.500.000
167CD300ACD300a moleculeKidney+4.490.001
168TMEM178Atransmembrane protein 178AKidney-4.480.000
169SEMA6Dsema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6DKidney-4.470.000
170CCL18chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)Kidney+4.450.012
171TCF21transcription factor 21Kidney-4.450.002
172SLAMF7SLAM family member 7Kidney+4.450.001
173PDE1Aphosphodiesterase 1A, calmodulin-dependentKidney-4.440.000
174MIR155HGMIR155 host geneKidney+4.440.001
175SOWAHAsosondowah ankyrin repeat domain family member AKidney-4.440.007
176HMGCS23-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)Kidney-4.430.036
177RBP4retinol binding protein 4, plasmaKidney-4.430.009
178SLFN13schlafen family member 13Kidney+4.320.000
179SLC16A3solute carrier family 16 (monocarboxylate transporter), member 3Kidney+4.240.000
180FAM26Ffamily with sequence similarity 26, member FKidney+4.180.000
181SPAG4sperm associated antigen 4Kidney+4.130.000
182EHD2EH-domain containing 2Kidney+4.120.000
183CXCL9chemokine (C-X-C motif) ligand 9Kidney+4.110.001
184LOXlysyl oxidaseKidney+4.100.000
185CCNE2cyclin E2Kidney+4.080.000
186ENO2enolase 2 (gamma, neuronal)Kidney+4.080.000
187COL23A1collagen, type XXIII, alpha 1Kidney+4.030.003
188RGS1regulator of G-protein signaling 1Kidney+4.030.000
189CD86CD86 moleculeKidney+3.990.000
190CYP2J2cytochrome P450, family 2, subfamily J, polypeptide 2Kidney+3.990.023
191HAPLN1hyaluronan and proteoglycan link protein 1Kidney+3.980.009
192TLR8toll-like receptor 8Kidney+3.980.000
193ST8SIA4ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4Kidney+3.900.000
194AHNAK2AHNAK nucleoprotein 2Kidney+3.900.000
195BIRC3baculoviral IAP repeat containing 3Kidney+3.880.000
196TTKTTK protein kinaseKidney+3.880.000
197HIST1H2AGhistone cluster 1, H2agKidney+3.870.007
198LILRB2leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2Kidney+3.870.000
199LOC100289026uncharacterized LOC100289026Kidney+3.860.006
200C4orf47chromosome 4 open reading frame 47Kidney+3.850.000
201INHBBinhibin, beta BKidney+3.840.001
202PLA2G7phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)Kidney+3.840.003
203CPceruloplasmin (ferroxidase)Kidney+3.830.021
204BRIP1BRCA1 interacting protein C-terminal helicase 1Kidney+3.830.003
205HMHA1histocompatibility (minor) HA-1Kidney+3.830.000
206GAS2L3growth arrest-specific 2 like 3Kidney+3.830.000
207TEX11testis expressed 11Kidney+3.790.029
208HILPDAhypoxia inducible lipid droplet-associatedKidney+3.790.000
209TREM2triggering receptor expressed on myeloid cells 2Kidney+3.790.000
210BHLHE41basic helix-loop-helix family, member e41Kidney+3.720.000
211TMCC1transmembrane and coiled-coil domain family 1Kidney+3.720.000
212KIF20Akinesin family member 20AKidney+3.720.000
213TPX2TPX2, microtubule-associatedKidney+3.700.000
214SEC16BSEC16 homolog B, endoplasmic reticulum export factorKidney+3.700.000
215PVT1Pvt1 oncogene (non-protein coding)Kidney+3.690.000
216TRDV3T cell receptor delta variable 3Kidney+3.640.000
217HTRA4HtrA serine peptidase 4Kidney+3.630.005
218TMEM45Atransmembrane protein 45AKidney+3.630.016
219SLC6A3solute carrier family 6 (neurotransmitter transporter), member 3Kidney+3.620.012
220CDKN2Acyclin-dependent kinase inhibitor 2AKidney+3.590.000
221RHOHras homolog family member HKidney+3.590.000
222PTPN22protein tyrosine phosphatase, non-receptor type 22 (lymphoid)Kidney+3.590.003
223NETO2neuropilin (NRP) and tolloid (TLL)-like 2Kidney+3.570.001
224NEK2NIMA-related kinase 2Kidney+3.570.000
225P2RX7purinergic receptor P2X, ligand gated ion channel, 7Kidney+3.570.000
226SIRPGsignal-regulatory protein gammaKidney+3.540.015
227ALOX5arachidonate 5-lipoxygenaseKidney+3.530.000
228TRDT cell receptor delta locusKidney+3.520.000
229TEN1TEN1 CST complex subunitKidney+3.500.000
230SLAMF8SLAM family member 8Kidney+3.500.001
231CCR5chemokine (C-C motif) receptor 5 (gene/pseudogene)Kidney+3.490.000
232BIN2bridging integrator 2Kidney+3.460.000
233TNFRSF4tumor necrosis factor receptor superfamily, member 4Kidney+3.440.001
234FCGR2CFc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)Kidney+3.420.000
235BRCA2breast cancer 2, early onsetKidney+3.390.000
236SLC17A4solute carrier family 17, member 4Kidney+3.380.019
237CXCL10chemokine (C-X-C motif) ligand 10Kidney+3.380.007
238PIK3R5phosphoinositide-3-kinase, regulatory subunit 5Kidney+3.370.000
239IGFBP3insulin-like growth factor binding protein 3Kidney+3.360.000
240VSIG1V-set and immunoglobulin domain containing 1Kidney+3.350.013
241ASPMabnormal spindle microtubule assemblyKidney+3.330.004
242HIST1H3Hhistone cluster 1, H3hKidney+3.320.012
243GIT2G protein-coupled receptor kinase interacting ArfGAP 2Kidney+3.300.000
244CDKN3cyclin-dependent kinase inhibitor 3Kidney+3.290.000
245FANCIFanconi anemia, complementation group IKidney+3.270.000
246CDC25Ccell division cycle 25CKidney+3.260.010
247DUSP4dual specificity phosphatase 4Kidney+3.260.003
248CCL5chemokine (C-C motif) ligand 5Kidney+3.240.003
249DTLdenticleless E3 ubiquitin protein ligase homolog (Drosophila)Kidney+3.230.000
250CXCL11chemokine (C-X-C motif) ligand 11Kidney+3.210.010
251CST7cystatin F (leukocystatin)Kidney+3.200.004
252TNFSF13Btumor necrosis factor (ligand) superfamily, member 13bKidney+3.190.000
253RAC2ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)Kidney+3.190.002
254PARVGparvin, gammaKidney+3.180.000
255BUB1BUB1 mitotic checkpoint serine/threonine kinaseKidney+3.180.012
256ZNF395zinc finger protein 395Kidney+3.170.021
257MCM10minichromosome maintenance 10 replication initiation factorKidney+3.170.007
258TMEM44transmembrane protein 44Kidney+3.150.000
259LOXL2lysyl oxidase-like 2Kidney+3.140.003
260CD8ACD8a moleculeKidney+3.140.011
261XCL1chemokine (C motif) ligand 1Kidney+3.120.002
262VNN2vanin 2Kidney+3.110.005
263CENPKcentromere protein KKidney+3.110.001
264RRM2ribonucleotide reductase M2Kidney+3.090.006
265CHPF2chondroitin polymerizing factor 2Kidney+3.090.000
266CRTAMcytotoxic and regulatory T cell moleculeKidney+3.080.012
267SCDstearoyl-CoA desaturase (delta-9-desaturase)Kidney+3.080.001
268IL7Rinterleukin 7 receptorKidney+3.070.018
269LPCAT1lysophosphatidylcholine acyltransferase 1Kidney+3.050.000
270LCKLCK proto-oncogene, Src family tyrosine kinaseKidney+3.050.000
271SAP30Sin3A-associated protein, 30kDaKidney+3.050.000
272PCSK6proprotein convertase subtilisin/kexin type 6Kidney+3.050.025
273TEAD4TEA domain family member 4Kidney+3.050.000
274SCARB1scavenger receptor class B, member 1Kidney+3.040.001
275CLEC12AC-type lectin domain family 12, member AKidney+3.030.003
276MYO9Bmyosin IXBKidney+3.010.001
277LILRB1leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1Kidney+3.010.002
278PRR11proline rich 11Kidney+3.000.001

Search GEO for disease gene expression data for Renal Cell Carcinoma.

Pathways for genes affiliated with Renal Cell Carcinoma

About this section

Pathways related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
10.5AKT1, HNF1A, HNF1B, PIK3CA
2
Show member pathways
10.5AKT1, FLCN, MET, PIK3CA, PTEN, VHL
3
Show member pathways
10.5AKT1, PIK3CA, VHL
410.5AKT1, MET, PIK3CA, PTEN, VHL
510.5AKT1, MET, PIK3CA
6
Show member pathways
10.5AKT1, MET, PIK3CA
710.5AKT1, MET, PIK3CA
8
Show member pathways
10.5AKT1, MET, PIK3CA, PTEN
910.5AKT1, PIK3CA, PTEN
1010.5AKT1, PIK3CA, PTEN
1110.5AKT1, PIK3CA, PTEN
1210.5AKT1, MET, PIK3CA, PTEN
13
Show member pathways
10.5AKT1, IL2, MET, PIK3CA
14
Show member pathways
10.5AKT1, IL2, PIK3CA
15
Show member pathways
10.5AKT1, IL2, PIK3CA
1610.5AKT1, IL2, MET, PIK3CA, PTEN

GO Terms for genes affiliated with Renal Cell Carcinoma

About this section

Biological processes related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of transcription initiation from RNA polymerase II promoterGO:006026111.2HNF1A, HNF1B
2endocrine pancreas developmentGO:003101811.0AKT1, HNF1A, HNF1B
3endothelial cell migrationGO:004354211.0PIK3CA, PTEN
4protein kinase B signalingGO:004349111.0AKT1, PIK3CA
5positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic processGO:200006010.9PTEN, RNF139
6fibroblast growth factor receptor signaling pathwayGO:000854310.8AKT1, IL2, PIK3CA, PTEN
7adaptive immune responseGO:000225010.8IL2, PIK3CA, TFE3
8response to oxidative stressGO:000697910.7AKT1, HNF1A, OGG1
9negative regulation of apoptotic processGO:004306610.7AKT1, HNF1B, IL2, PTEN, VHL
10negative regulation of cell migrationGO:003033610.6FLCN, KANK1, PTEN
11liver developmentGO:000188910.6HNF1A, HNF1B, PIK3CA
12cellular response to hypoxiaGO:007145610.5AKT1, PTEN, VHL
13positive regulation of transcription from RNA polymerase II promoterGO:004594410.4AKT1, FLCN, HNF1A, HNF1B, IL2, MET
14neurotrophin TRK receptor signaling pathwayGO:004801110.2AKT1, IL2, PIK3CA, PTEN

Sources for Renal Cell Carcinoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet